Core Insights - Mingyu Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as joint sponsors [1] - The company, established in 2018, is a biotechnology innovator with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody (bsAb) [1] - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 in clinical stages, and expects to generate revenue from its autoimmune projects soon [1] - The oncology projects focus on advancing ADC monotherapy for later-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to innovate first-line cancer treatment [1]
明宇制药递表港交所主板
Zhi Tong Cai Jing·2025-11-24 13:13